Clinical trials: Anxiety Disorder
Generalized Anxiety Disorder
A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder (GAD)
This study will assess the long-term safety and tolerability of 350 to 600 mg/day of PD 0332334 administered in split dose (twice daily) in subjects with Generalized Anxiety Disorder.
- Trial name
- NCT00735267
- Testing
- PD 0332334
- Where
- 93 sites in United States
- Volunteers
- 468 people
- Sponsor
- Pfizer
Social Phobia
A Study To Evaluate The Effect Of GW876008 On The Pharmacokinetics Of Oral Contraceptive Pills
This study will be conducted in healthy female volunteers to investigate the effect of GW876008 on the pharmacokinetics of oral contraceptive pills.
- Trial name
- NCT00508911
- Testing
- GW876008, COC
- Where
- United Kingdom
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Recurrent Pregnancy Loss, Anxiety Disorders
Right Prefrontal Autonomic Mapping in Recurrent Pregnancy Loss With Comorbid Anxiety
Recurrent pregnancy loss is often accompanied by substantial anxiety and may also be associated with autonomic imbalance and increased long-term cardiovascular vulnerability.
- Trial name
- NCT06968026
- Testing
- repetitive transcranial magnetic stimulation(rTMS)
- Where
- 4 sites in China
- Volunteers
- 55 people
- Sponsor
- Shenyang Jinghua Hospital
Mood, Depression Disorders
Technology Exposure and Child Health: Wellness Impact and Social Effects: An Observational Product Registry Study
The goal of this study is to understand how children's mobile device usage (smartphones or tablets), including social media use and online games, are related to their mental wellness and mental health, as well as some aspects of…
- Conditions
- Mood, Depression Disorders, Anxiety Disorders, Sleep
- Trial name
- TECHWISE (NCT06664944)
- Where
- United States
- Volunteers
- 912 people, healthy volunteers welcome
- Sponsor
- Aura
Social Anxiety Disorder
Escitalopram in Patients With Social Anxiety Disorder
The purpose of this study is to evaluate the effect of escitalopram after 12 weeks of treatment in patients with Social Anxiety Disorder (SAD), to evaluate proportion of patients who respond to escitalopram during the treatment…
- Trial name
- NCT00902226
- Testing
- Escitalopram
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- H. Lundbeck A/S
Anxiety Disorders
Duloxetine Compared With Placebo in the Prevention of Relapse in Generalized Anxiety Disorder
This is a clinical trial assessing the time to relapse of anxiety symptoms among patients with generalized anxiety disorder who have responded to duloxetine therapy.
- Trial name
- NCT00122863
- Testing
- Duloxetine Hydrochloride
- Where
- 47 sites in United States, Austria and 5 more
- Volunteers
- 380 people
- Sponsor
- Eli Lilly and Company
Generalized Anxiety
An Eight-week Study to Evaluate the Efficacy and Safety of 2 Doses of Saredutant in Patients With Generalized Anxiety Disorder
The primary objective is to evaluate the efficacy of two fixed doses (100 mg and 30 mg once daily) of saredutant compared to placebo in patients with generalized anxiety disorder.
- Trial name
- NCT00390533
- Testing
- Saredutant
- Where
- 2 sites in United States, Australia
- Volunteers
- 428 people
- Sponsor
- Sanofi
Hypothermia
Study to Determine the Effects of Pre-warming on OR Patient Temperatures and Surgical Outcomes
The application of active warming to patients whether awake or under general anesthesia has been proven safe in numerous studies and it is common practice to use warmers.
- Trial name
- NCT02177903
- Testing
- Bair Paws Patient Adjustable Warming System
- Where
- Canada
- Volunteers
- 220 people
- Sponsor
- Solventum US LLC
Depression Disorders, Anxiety Disorders
Pivotal U.S. Clinical Validation of AI-COA® for Depression and Anxiety
This study is a large-scale pivotal clinical validation of the AI-COA® software device. The purpose is to confirm the tool's accuracy and performance across a demographically diverse population of adults with Major Depressive…
- Trial name
- SEQUOIA-3 (NCT07279038)
- Where
- United States
- Volunteers
- 650 people
- Sponsor
- Deliberate Solutions Inc.
Parkinson Disease
Comparative Controlled Study of Analgesic, Antiasthenic and Anti-Anxiety Effects of Xenon in Patients With Parkinson's Disease
This study evaluates the hypothesis that the gas mixture with xenon will have a positive effect on the symptoms in patients with Parkinson's Disease.
- Trial name
- NCT04097080
- Testing
- NBTX-001, Standard of Care
- Where
- 2 sites in Russia
- Volunteers
- 60 people
- Sponsor
- Nobilis Therapeutics Inc.
Panic Disorder
Study Evaluating Venlafaxine ER in Adults With Panic Disorder
The primary objective of this study is to determine the efficacy, safety, and tolerability of a flexible dose of venlafaxine extended-release (ER) capsules administered for 10 weeks in the treatment of adult outpatients with…
- Trial name
- NCT00038896
- Testing
- Venlafaxine ER
- Volunteers
- 343 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Trichotillomania
A Study in Patients With Trichotillomania
The purpose of this study is to explore the safety, tolerability and activity of SXC-2023 when dosed for 6 weeks versus placebo in adult patients with moderate to severe Trichotillomania.
- Trial name
- TTM (NCT03797521)
- Testing
- SXC-2023
- Where
- 13 sites in United States
- Volunteers
- 128 people
- Sponsor
- Promentis Pharmaceuticals, Inc.
Depressive Symptoms, Anxiety Disorders
Messaging Therapy for Depression and Anxiety: A Longitudinal Effectiveness Study
Therapies delivered via technology have been developed to improve accessibility, however, there is limited research regarding messaging therapy in particular, and none that we know of utilizing a longitudinal effectiveness…
- Trial name
- NCT03699488
- Testing
- psychotherapy via asynchronous message
- Volunteers
- 12,980 people
- Sponsor
- Talkspace
Social Phobia
Long-term Study Of Paroxetine in Women and Men
This study is designed to evaluate the efficacy and safety in Social Anxiety Disorder (SAD)
- Trial name
- SAD (NCT00264654)
- Testing
- BRL29060A, paroxetine hydrochloride hydrate
- Where
- 3 sites in Japan
- Volunteers
- 50 people
- Sponsor
- GlaxoSmithKline
Anxiety
Electrical Vestibular Nerve Stimulation (VeNS) as a Treatment for Anxiety
Anxiety is known to be one of the most common health concerns in in the general population, and the most common mental health issue, and has been associated with several health consequences.
- Trial name
- NCT04999709
- Testing
- VeNS
- Where
- Hong Kong
- Volunteers
- 74 people
- Sponsor
- Neurovalens Ltd.
Anxiety Disorder Generalized
А Dose-finding Study to Assess the Efficacy and Safety of CD-008-0045 in Patients With Generalized Anxiety Disorder
This is a multicenter, randomized, double-blind, placebo-controlled, dose-finding pilot study to assess the efficacy and safety of CD-008-0045 in patients with Generalized Anxiety Disorder (GAD).
- Trial name
- NCT04524975
- Testing
- CD-008-0045
- Where
- 15 sites in Russia
- Volunteers
- 129 people
- Sponsor
- ChemRar Research and Development Institute, LLC
Alzheimer Disease, Agitation,Psychomotor
Clinical Trial on Agitation in Alzheimer's Dementia
The purpose of this study is to assess the efficacy of the oral medication IGC-AD1, a THC-based (Delta-9-Tetrahydrocannabinol) formulation administered twice a day on Agitation in patients with mild to severe dementia from…
- Conditions
- Alzheimer Disease, Agitation,Psychomotor, Care Giving Burden, NPS
- Trial name
- CALMA (NCT05543681)
- Testing
- IGC-AD1-Active
- Where
- 28 sites in United States, Canada and 1 more
- Volunteers
- 164 people
- Sponsor
- IGC Pharma, LLC
Emotional Dysregulation, Therapeutic Alliance
Effectiveness of the SoundHeal Multi-Sensory Integrative Therapy Among Justice-Involved Youth
Emotional dysregulation in justice-involved youth (JIY) is a condition that significantly impacts young people, their families, and juvenile justice and public health systems.
- Conditions
- Emotional Dysregulation, Therapeutic Alliance, Depression Disorder, Anxiety Disorders
- Trial name
- HEAL-SLOJSC (NCT07364799)
- Testing
- Multi-sensory emotional regulation intervention (Heal)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- SoundHeal
Depression - Major Depressive Disorder, Anxiety
Singula Phase 0.1 Primary Care Pilot
This prospective, single-arm, observational pilot study evaluates a clinical decision support system developed by Singula Health for use in primary care.
- Trial name
- NCT07834684
- Where
- 2 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Singula Health, Inc.
Social Anxiety Disorder
A Phase 2 Study of BNC210 for the Acute Treatment of Social Anxiety Disorder
The purpose of this study is to assess the effects of an acute dose of BNC210 compared to placebo on reducing anxiety provoked by a speaking challenge and measured using the Subjective Units of Distress Scale (SUDS) in patients…
- Trial name
- PREVAIL (NCT05193409)
- Testing
- 225 mg BNC210, 675 mg BNC210
- Where
- 15 sites in United States
- Volunteers
- 151 people
- Sponsor
- Bionomics Limited